Chronic Lymphocytic Leukemia
📧 Sign up to get email alerts when something new happens for Chronic Lymphocytic Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-06-22Clinical Trial Update: Theophylline in Treating Patients With In Situ, Stage I, or Stage II Chronic Lymphocytic Leukemia [Phase 2]
Phase 2 trial updating the use of theophylline to treat chronic lymphocytic leukemia in situ, stage I, or stage II.
-
CLINICAL_TRIALS trial_result · 2023-06-18Clinical Trial Update: Fludarabine With or Without Cyclophosphamide in Treating Patients With Chronic Lymphocytic Leukemia [Phase 3]
Phase 3 trial assessing fludarabine with or without cyclophosphamide in chronic lymphocytic leukemia has completed.
-
CLINICAL_TRIALS trial_result · 2023-06-15Clinical Trial Update: Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy [Phase 2]
Phase 2 trial of Umbralisib plus Ublituximab (U2) in progressive chronic lymphocytic leukemia after novel therapy was terminated; results po…
-
CLINICAL_TRIALS trial_result · 2023-06-13Clinical Trial Update: A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia [Phase 1, Phase 2]
Clinical trial update for ABT-263 in relapsed or refractory chronic lymphocytic leukemia (Phase 1/Phase 2) completed with results posted.
-
CLINICAL_TRIALS trial_result · 2023-06-09Clinical Trial Update: High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant [Phase 2]
Phase 2 clinical trial evaluating high-dose cyclophosphamide, tacrolimus, and mycophenolate mofetil to prevent graft-versus-host disease in …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-06-07Clinical Trial Update: A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors [Phase 1, Phase 2]
Phase 1/2 clinical trial update for ASN002 in relapsed/refractory lymphoma and advanced solid tumors; the study status is TERMINATED with re…
-
CLINICAL_TRIALS trial_result · 2023-06-05Clinical Trial Update: ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL [Phase 3]
A Phase 3 trial comparing ICP-022 to chlorambucil plus rituximab in untreated CLL/SLL is underway, with status currently unknown.
-
FDA approval · 2023-06-05FDA Approved: BENDAMUSTINE — Original Application (Meitheal Pharmaceuticals Inc.)
The FDA approved the original application for Bendamustine HCl from Meitheal Pharmaceuticals Inc., sanctioning a generic version of bendamus…
-
CLINICAL_TRIALS trial_result · 2023-05-22Clinical Trial Update: A Safety, Tolerability, Pharmacokinetics and Efficacy Study of GB261 in B-Cell NHL and CLL. [Phase 1, Phase 2]
A safety, tolerability, pharmacokinetics and efficacy study of GB261 in B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia is in P…
-
CLINICAL_TRIALS trial_result · 2023-04-27Clinical Trial Update: Reduced Intensity Conditioning Transplant Using Haploidentical Donors [Phase 2]
Phase 2 clinical trial investigating reduced intensity conditioning transplant using haploidentical donors for various hematologic malignanc…
-
CLINICAL_TRIALS trial_result · 2023-04-19Clinical Trial Update: Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma [Phase 2]
A Phase 2 trial evaluating the combination of ibrutinib, fludarabine, and pembrolizumab in high-risk or relapsed/refractory chronic lymphocy…
-
CLINICAL_TRIALS trial_result · 2023-03-30Clinical Trial Update: Immune Response After Pneumococcal Vaccination in Patient With Chronic Lymphocytic Leukemia [Phase 4]
Phase 4 clinical trial update evaluating immune response after pneumococcal vaccination in a patient with chronic lymphocytic leukemia.
-
FDA approval · 2023-03-24FDA Approved: LENALIDOMIDE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for lenalidomide submitted by Sun Pharmaceutical Industries, Inc.
-
FDA approval · 2023-03-24FDA Approved: LENALIDOMIDE — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for Lenalidomide submitted by Aurobindo Pharma Limited to support the continued availability of …
-
CLINICAL_TRIALS trial_result · 2023-03-24Clinical Trial Update: TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL) [Phase 2]
Phase 2 trial evaluating umbralisib (TGR-1202) in treatment-naïve chronic lymphocytic leukemia was terminated; results were posted.
-
CLINICAL_TRIALS trial_result · 2023-03-23Clinical Trial Update: Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL) [Phase 2]
Phase II trial update of eltrombopag in chronic lymphocytic leukemia has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2023-03-21Clinical Trial Update: Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas [Phase 2]
Phase 2 trial of pembrolizumab alone or with idelalisib or ibrutinib in relapsed/refractory chronic lymphocytic leukemia or various low-grad…
-
FDA approval · 2023-03-06FDA Approved: LENALIDOMIDE — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approved Sun Pharmaceutical Industries' generic lenalidomide (LENALIDOMIDE) under ANDA211846.
-
FDA approval · 2023-03-06FDA Approved: LENALIDOMIDE — Original Application (Mylan Pharmaceuticals Inc.)
FDA approved Lenalidomide from Mylan Pharmaceuticals as an original application (ANDA), marking the approval of a generic lenalidomide.
-
FDA approval · 2023-03-06FDA Approved: LENALIDOMIDE — Original Application (Aurobindo Pharma Limited)
FDA approved Lenalidomide as a generic product under an original application from Aurobindo Pharma Limited.
-
FDA approval · 2023-03-06FDA Approved: LENALIDOMIDE — Original Application (Teva Pharmaceuticals, Inc.)
FDA approved a generic lenalidomide product for Teva under ANDA201452, expanding access to lenalidomide formulations.
-
FDA approval · 2023-03-06FDA Approved: LENALIDOMIDE — Original Application (Alvogen, Inc.)
FDA approved Alvogen, Inc.'s original Abbreviated New Drug Application for a generic lenalidomide product (ANDA 210480).
-
FDA approval · 2023-03-06FDA Approved: LENALIDOMIDE — Original Application (EXELAN PHARMACEUTICALS INC.)
FDA approves a generic lenalidomide product from Exelan Pharmaceuticals under an original application. The drug is indicated for several hem…
-
CLINICAL_TRIALS trial_result · 2023-02-22Clinical Trial Update: A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent). [Phase 3]
Phase 3 trial evaluating venetoclax monotherapy in relapsed or refractory chronic lymphocytic leukemia; results posted in 2023.
-
CLINICAL_TRIALS trial_result · 2023-02-21Clinical Trial Update: A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07 [Phase 3]
Phase 3 extension study in chronic lymphocytic leukemia/small lymphocytic lymphoma evaluating duvelisib with ofatumumab has completed enroll…